Pfizer’s Xeljanz Could See Narrower Label And New REMS Due To CV And Malignancy Risks

 
• By Sue Sutter
  
x-ray hands, rheumatoid arthritis
A Xeljanz study in high-risk rheumatoid arthritis patients has raised safety concerns. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United States

More from North America